Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Artículo Open Access |
| Publicado: |
Wiley
2025
|
| Materias: | |
| Acceso en línea: | https://onlinelibrary.wiley.com/doi/10.1111/php.70025 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1867011293017276416 |
|---|---|
| author | Bárbara Evelyn Santos de Lima Rebeca Barros Nascimento Ana Paula Mariano Santos Ginez Maria Stella Moreira Rebeca Boltes Cecatto Rodrigo Labat Marcos Maria Fernanda Setúbal Destro Rodrigues |
| author_facet | Bárbara Evelyn Santos de Lima Rebeca Barros Nascimento Ana Paula Mariano Santos Ginez Maria Stella Moreira Rebeca Boltes Cecatto Rodrigo Labat Marcos Maria Fernanda Setúbal Destro Rodrigues Bárbara Evelyn Santos de Lima Rebeca Barros Nascimento Ana Paula Mariano Santos Ginez Maria Stella Moreira Rebeca Boltes Cecatto Rodrigo Labat Marcos Maria Fernanda Setúbal Destro Rodrigues |
| collection | Wiley Open Access |
| contents | Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review Bárbara Evelyn Santos de Lima Rebeca Barros Nascimento Ana Paula Mariano Santos Ginez Maria Stella Moreira Rebeca Boltes Cecatto Rodrigo Labat Marcos Maria Fernanda Setúbal Destro Rodrigues Photochemistry and Photobiology Abstract Cancer is a chronic disease responsible for millions of deaths annually. Its multifaceted profile, with diverse types and anatomical locations, complicates treatment, often limited to surgery, radiotherapy, and chemotherapy. These treatments are frequently associated with increased tumor aggressiveness and recurrence, highlighting the urgent need for new, less invasive therapies. Recent studies suggest that blue light (BL; 450–470 nm) may offer anti‐tumor and pro‐apoptotic effects, making it a promising alternative for cancer treatment. However, its cellular and molecular mechanisms remain unclear. This qualitative systematic review, conducted in accordance with PRISMA guidelines, analyzed 37 in vitro and in vivo studies published between 2002 and 2024, retrieved from databases including MEDLINE/PubMed, EMBASE, and LILACS, with a focus on the effects of photobiomodulation (PBM) with blue light (450–470 nm) in pre‐clinical cancer models. BL demonstrated anti‐tumor potential by reducing cell viability, proliferation, migration, and invasion, as well as increasing ROS production and inducing apoptosis. In animal models, BL also inhibited tumor growth, metastasis, and improved survival. Despite the encouraging findings, considerable methodological heterogeneity and insufficient reporting of dosimetric parameters compromise the reproducibility and comparability of results across studies. These findings underscore the therapeutic potential of BL in oncology and highlight the need for standardized protocols to support clinical translation. 10.1111/php.70025 http://creativecommons.org/licenses/by/4.0/ |
| doi_str_mv | 10.1111/php.70025 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_php_70025 |
| institution | Wiley Open Access |
| license_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review Bárbara Evelyn Santos de Lima Rebeca Barros Nascimento Ana Paula Mariano Santos Ginez Maria Stella Moreira Rebeca Boltes Cecatto Rodrigo Labat Marcos Maria Fernanda Setúbal Destro Rodrigues Photochemistry and Photobiology Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review Bárbara Evelyn Santos de Lima Rebeca Barros Nascimento Ana Paula Mariano Santos Ginez Maria Stella Moreira Rebeca Boltes Cecatto Rodrigo Labat Marcos Maria Fernanda Setúbal Destro Rodrigues Photochemistry and Photobiology Abstract Cancer is a chronic disease responsible for millions of deaths annually. Its multifaceted profile, with diverse types and anatomical locations, complicates treatment, often limited to surgery, radiotherapy, and chemotherapy. These treatments are frequently associated with increased tumor aggressiveness and recurrence, highlighting the urgent need for new, less invasive therapies. Recent studies suggest that blue light (BL; 450–470 nm) may offer anti‐tumor and pro‐apoptotic effects, making it a promising alternative for cancer treatment. However, its cellular and molecular mechanisms remain unclear. This qualitative systematic review, conducted in accordance with PRISMA guidelines, analyzed 37 in vitro and in vivo studies published between 2002 and 2024, retrieved from databases including MEDLINE/PubMed, EMBASE, and LILACS, with a focus on the effects of photobiomodulation (PBM) with blue light (450–470 nm) in pre‐clinical cancer models. BL demonstrated anti‐tumor potential by reducing cell viability, proliferation, migration, and invasion, as well as increasing ROS production and inducing apoptosis. In animal models, BL also inhibited tumor growth, metastasis, and improved survival. Despite the encouraging findings, considerable methodological heterogeneity and insufficient reporting of dosimetric parameters compromise the reproducibility and comparability of results across studies. These findings underscore the therapeutic potential of BL in oncology and highlight the need for standardized protocols to support clinical translation. 10.1111/php.70025 http://creativecommons.org/licenses/by/4.0/ |
| title | Harnessing blue light photobiomodulation for cancer therapy: Evidence from a systematic review |
| topic | Photochemistry and Photobiology |
| url | https://onlinelibrary.wiley.com/doi/10.1111/php.70025 |